Type 1 diabetes trials in Norway

1 of 4 trials · From ClinicalTrials.gov, checked 12 November 2026. Ask the study team whether a trial fits you.

• No phaseTaking people
  A Pan-European Post-Authorisation Safety Study: Risk of Pancreatic Cancer Among Type 2 Diabetes Patients Who Initiated Exenatide as Compared With Those Who Initiated Other Non-Glucagon-Like Peptide 1 Receptor Agonists Based Glucose Lowering Drugs

  Where

  Bergen

  Age

  18 years to 99 years

  People

  24,000 worldwide

  Run by

  AstraZeneca

  See details and how to joinNCT05663515